论文部分内容阅读
28例可评价患者,中数年龄60岁。13例初治,3例Ⅱ期,10例Ⅲ期(Durie和Salmon分期系统)。余15例为复治患者。26例为IgG或IgA型MM;肿瘤细胞总量(TCM)运用Salmon或Wampler方法计算。1例非分泌型MM伴皮下肿块,另1例本周氏MM,分别根据瘤块大小和本周氏蛋白尿量消长加以判断。治疗方法,长春新碱1mg/m~2,阿霉素15mg/m~2和马法兰7mg/m~2静注,第1、15、29、43天,卡氮芥40mg/m~2静注,第1天,地塞米松25mg/m~2静注,第1-4、15-18、29-32、43-46天。有效者57天后重复直到TCM减少至最大程度。发生严重骨髓抑制(白细胞<2000/mm~3,血小板<10万/mm~3)的患者阿霉素、马法兰、卡
28 evaluable patients, the median age of 60 years. 13 cases were initially treated, 3 cases were in stage II and 10 cases were in stage III (Durie and Salmon staging system). More than 15 cases of retreatment patients. 26 cases were IgG or IgA type MM; total tumor cells (TCM) using Salmon or Wampler method. 1 case of non-secretory MM with subcutaneous tumor, and the other 1 case of this week’s MM, respectively, according to the size of the tumor block and this week’s proteinuria volume increase to be judged. Treatment, vincristine 1mg / m ~ 2, doxorubicin 15mg / m ~ 2 and melphalan 7mg / m ~ 2 intravenous injection on the 1st, 15th, 29th and 43th days, Carmustine 40mg / m ~ 2 intravenous , The first day, dexamethasone 25mg / m ~ 2 intravenous injection, the first 1-4,15-18,29-32,43-46 days. Effector 57 days after repeated until TCM reduced to the maximum extent. In patients with severe myelosuppression (white blood cells <2000 / mm ~ 3, platelets <100,000 / mm ~ 3), doxorubicin, melphalan,